• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial

    Chelsea Pratt
    Oct. 21, 2016 05:58AM PST
    Biotech Investing

    CEL-SCI has started working on a response to the FDA and will work diligently with the FDA to seek to have the partial clinical hold lifted.

    CEL-SCI Corporation (NYSE MKT:CVM) announced today: following up on our press release issued on September 26, 2016, we have received the Partial Clinical Hold letter from the U.S. Food and Drug Administration
    (FDA). CEL-SCI has started working on a response to the FDA and will work diligently with the FDA to seek to have the partial clinical hold lifted.
    About CEL-SCI Corporation
    CEL-SCI’s work is focused on finding the best way to activate the immune
    system to fight cancer and infectious diseases. Its lead investigational
    immunotherapy, Multikine* (Leukocyte Interleukin, Injection), is
    currently being studied in a pivotal Phase 3 clinical trial as a
    potential neoadjuvant treatment for patients with squamous cell
    carcinoma of the head and neck. Subject to the partial clinical hold,
    the study was designed with the objective that, if the study endpoint,
    which is an improvement in overall survival of the subjects treated with
    the Multikine treatment regimen plus the current standard of care (SOC)
    as compared to subjects treated with the current SOC only, is satisfied,
    the study results will be used to support applications that the Company
    plans to submit to regulatory agencies in order to seek commercial
    marketing approvals for Multikine in major markets around the world.
    Additional clinical indications for Multikine that are being
    investigated include the treatment of cervical dysplasia in HIV/HPV
    co-infected women, and the treatment of peri-anal warts in HIV/HPV
    co-infected men and women. A Phase 1 trial of the former indication
    (treatment of cervical dysplasia in HIV/HPV co-infected women) has been
    completed at the University of Maryland. The latter indication
    (treatment of peri-anal warts in HIV/HPV co-infected men and women) is
    being studied in a Phase 1 trial at UCSF. CEL-SCI has issued patents on
    Multikine from the US, Europe, China, and Japan.
    CEL-SCI also is developing its pre-clinical L.E.A.P.S. (Ligand Epitope
    Antigen Presentation System) technology for the potential treatment of
    pandemic influenza in hospitalized patients and as a potential vaccine
    for the treatment of rheumatoid arthritis.
    The Company has operations in Vienna, Virginia, and in/near Baltimore,
    Maryland.
    Forward-Looking Statements
    This press release contains forward-looking statements within the
    meaning of Section 27A of the Securities Act of 1933, as amended, and
    Section 21E of the Securities Exchange Act of 1934, as amended. When
    used in this press release, the words “intends,” “believes,”
    “anticipated,” “plans” and “expects,” and similar expressions, are
    intended to identify forward-looking statements. Such statements are
    subject to risks and uncertainties that could cause actual results to
    differ materially from those projected. Factors that could cause or
    contribute to such differences include, an inability to duplicate the
    clinical results demonstrated in clinical studies, timely development of
    any potential products that can be shown to be safe and effective,
    receiving necessary regulatory approvals, difficulties in manufacturing
    any of the Company’s potential products, inability to raise the
    necessary capital and the risk factors set forth from time to time in
    CEL-SCI Corporation’s filings with the Securities and Exchange
    Commission, including but not limited to its report on Form 10-K for the
    year ended September 30, 2015. The Company undertakes no obligation to
    publicly release the result of any revision to these forward-looking
    statements which may be made to reflect the events or circumstances
    after the date hereof or to reflect the occurrence of unanticipated
    events.
    *Multikine (Leukocyte Interleukin, Injection) is the trademark that
    CEL-SCI has registered for this investigational therapy, and this
    proprietary name is subject to FDA review in connection with the
    Company’s future anticipated regulatory submission for approval.
    Multikine has not been licensed or approved for sale, barter or exchange
    by the FDA or any other regulatory agency. Similarly, its safety or
    efficacy have not been established for any use. Moreover, no definitive
    conclusions can be drawn from the early-phase, clinical-trials data
    involving the investigational therapy Multikine. Further research is
    required, and early-phase clinical trial results must be confirmed in
    the Phase 3 clinical trial of this investigational therapy that is in
    progress and that is currently subject to a clinical hold on enrollment
    of additional new patients.

    clinical resultsclinical studiesclinical trialsclinical holdchinaclinical trial results
    The Conversation (0)

    Go Deeper

    AI Powered
    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

    Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×